Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Go back to Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
(NASDAQ: FULC) Delayed: 3.72 -0.02 (0.53%)
Previous Close $3.74    52 Week High $ 
Open $3.75    52 Week Low $ 
Day High $3.76    P/E N/A 
Day Low $3.71    EPS $ 
Volume 205,647